Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 2,365 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bacterial Infection Clear all
Completed Phase 2Phase 3 Interventional Results available

PinPointe FootLaser for the Treatment of Onychomycosis

NCT00935649
View directory record Official record
Conditions
Infected Toenails, Onychomycosis
Interventions
PinPointe FootLaser
Device
Lead sponsor
PathoLase, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Rochester, New York • San Antonio, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 25, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

VELOCITY: An Anthrax Vaccine Clinical Study

NCT03877926
View directory record Official record
Conditions
Anthrax
Interventions
AV7909, BioThrax
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 65 Years
Enrollment
3,689 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 31 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 25, 2026, 8:55 AM EDT
Completed Phase 1 Interventional

A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

NCT01946568
View directory record Official record
Conditions
Bacterial Infections.
Interventions
Dalbavancin
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
3 Months to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 25, 2026, 8:55 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Treatment for Presumed Ocular Histoplasmosis

NCT01790893
View directory record Official record
Conditions
Ocular Histoplasmosis
Interventions
aflibercept
Drug
Lead sponsor
John Kitchens, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
Augusta, Georgia • Lexington, Kentucky • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 25, 2026, 8:55 AM EDT
Completed Phase 1 Interventional

Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine Metabolites

NCT00000826
View directory record Official record
Conditions
Bacterial Infections, Mycoses, HIV Infections
Interventions
Clarithromycin, Rifabutin, Sulfamethoxazole-Trimethoprim, Dapsone, Fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
2
States / cities
San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 25, 2026, 8:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea

NCT02067676
View directory record Official record
Conditions
Campylobacter Infection
Interventions
Capsule-Conjugate Campylobacter Vaccine (CJCV1), Alhydrogel®, aluminum hydroxide adjuvant (alum)
Biological · Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 25, 2026, 8:55 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01968733
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Moxifloxacin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
62
States / cities
Mobile, Alabama • Little Rock, Arkansas • Chino, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 25, 2026, 8:55 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

MSSA and MRSA Screening in Patients Undergoing Elective TJA: the Benefits of Next-generation Sequencing

NCT04574752
View directory record Official record
Conditions
Staphylococcus Aureus, Next Generation Sequencing, Total Joint Arthroplasty
Interventions
next generation sequencing
Diagnostic Test
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years to 80 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 25, 2026, 8:55 AM EDT
Recruiting Phase 4 Interventional

Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

NCT07285785
View directory record Official record
Conditions
Diarrhea, Gastroenteritis, Bacterial Infection, Acute Diarrhea
Interventions
Rifaximin 200 mg Tablet, Oral Rehydration Therapy (ORT)
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Lynwood, California • Hialeah, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 25, 2026, 8:55 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of a Prebiotic and Probiotic Supplement to Provide Relief From Symptoms Associated With Bacterial Vaginosis and Yeast Infections.

NCT06665126
View directory record Official record
Conditions
Bacterial Vaginosis, Yeast Infection
Interventions
Prebiotic + Probiotic Supplement, Active Placebo Supplement, Excipient Placebo Supplement
Dietary Supplement
Lead sponsor
Happy V
Industry
Eligibility
25 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 25, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants

NCT01827358
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Mupirocin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 24 Months
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 25, 2026, 8:55 AM EDT
Completed Not applicable Interventional Results available

Antibiotic Selection Using Next Generation Sequencing vs Urine Culture

NCT04404855
View directory record Official record
Conditions
Kidney Stone, Renal Stone, Infection, Bacterial
Interventions
NGS + Antibiotic Recommendation, Standard of Care treatment
Other · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 25, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

NCT00896493
View directory record Official record
Conditions
Mycoses, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin, Cutaneous T-cell Lymphoma
Interventions
anti-thymocyte globulin, cyclosporine, Lymphoid radiation
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 25, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

NCT04092452
View directory record Official record
Conditions
Acne Inversa
Interventions
PF-06650833, PF-06700841, PF-06826647, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
63
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 25, 2026, 8:55 AM EDT
Recruiting Early Phase 1 Interventional

Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease

NCT06611111
View directory record Official record
Conditions
Post-Treatment Lyme Disease
Interventions
Ceftriaxone (Rocephin®), Dextrose 5% (D5W)
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
East Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 25, 2026, 8:55 AM EDT
Completed No phase listed Observational

Mucormycosis in COVID-19

NCT04935463
View directory record Official record
Conditions
Covid19, Mucormycosis, Aspergillosis, Candida Infection
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
Not listed
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 25, 2026, 8:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Combination Primary Care and Prevention Services for Women Who Inject Drugs and Exchange Sex in Seattle, Washington

NCT06187064
View directory record Official record
Conditions
Opioid Use Disorder, HIV Infections, Chlamydia, Gonorrhea, Syphilis, Trichomonas
Interventions
Mobile Van Clinic
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 25, 2026, 8:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

NCT01214993
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Tuberculosis
Interventions
GSK1349572, Placebo, Iohexol Injection, Para-aminohippurate infusion
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 25, 2026, 8:55 AM EDT
Completed No phase listed Observational

Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection

NCT04317963
View directory record Official record
Conditions
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Interventions
Bezlotoxumab, Standard CDI treatment
Biological · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 25, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

Cross-linking for Corneal Ulcers Treatment Trial

NCT02570321
View directory record Official record
Conditions
Corneal Ulcer, Infectious Keratitis, Bacterial Ulcer, Fungal Ulcer
Interventions
Corneal Cross-linking, Anti Fungal Drug
Procedure · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 25, 2026, 8:55 AM EDT
Completed No phase listed Observational

Potential Nosocomial Infection Prevention Via Modification of Anesthesia Intraoperative Aseptic Practice

NCT00617006
View directory record Official record
Conditions
Nosocomial Infections
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 15, 2008 · Synced Oct 25, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.

NCT00356915
View directory record Official record
Conditions
Onychomycosis
Interventions
Itraconazole 100mg capsules, Itraconazole 200mg tablets, Placebo tablets
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
16 Years to 75 Years
Enrollment
1,381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
52
States / cities
Birmingham, Alabama • Tuscon, Arizona • Hot Springs, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 25, 2026, 8:55 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection

NCT03597347
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)
Interventions
Molgramostim nebulizer solution, PARI eFlow nebulizer system
Drug · Device
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 25, 2026, 8:55 AM EDT
Completed Phase 3 Interventional

An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies

NCT00000714
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
21
States / cities
Miami, Florida • Chicago, Illinois • Indianapolis, Indiana + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 25, 2026, 8:55 AM EDT